Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Quest Diagnostics reports robust Q4 earnings, eyes growth through acquisitions

Quest Diagnostics demonstrated strong financial performance in Q4 2024, driven by revenue growth and strategic acquisitions.
The company's focus on core customers, operational improvements, and margin expansion sets a positive trajectory for future growth.
While challenges like integration and margin management exist, opportunities from acquisitions and regulatory support offer avenues for sustained growth.
Overall, Quest Diagnostics remains well-positioned to capitalize on market opportunities and drive shareholder value.

Quest Diagnostics posts strong Q1 results, eyes growth opportunities

Quest Diagnostics delivered robust financial results in Q1 2025, driven by revenue growth and operational efficiency. The company's strategic focus on core clinical customers and expansion into new growth areas positions it well for future success. While facing challenges in regulatory compliance and operational optimization, Quest Diagnostics remains proactive in addressing industry changes. Investments in technology, collaborations, and strategic initiatives underscore Quest's commitment to innovation and sustainable growth.

Quest Diagnostics reports robust Q2 growth and strategic acquisitions

Quest Diagnostics delivered impressive Q2 results, showcasing strong financial performance and strategic growth initiatives. While facing regulatory challenges and market dynamics, the company's focus on innovation and operational excellence positions it well for future success. With raised guidance and a strong emphasis on advanced diagnostics and acquisitions, Quest Diagnostics is poised for continued growth and market leadership.

Quest Diagnostics excels in Q3 2025, eyes growth in advanced diagnostics

Quest Diagnostics delivered robust Q3 2025 results, showcasing revenue growth, increased EPS, and strong cash flow from operations. Strategic initiatives in advanced diagnostics, acquisitions, and partnerships are bolstering growth across key channels and driving momentum. While facing regulatory challenges and competition, Quest Diagnostics is well-positioned to capitalize on opportunities in consumer health and advanced diagnostics.

Quest Diagnostics reports robust Q4 earnings, eyes growth opportunities

Quest Diagnostics delivered strong financial performance in Q4 2025, driven by revenue growth and operational efficiency. The company's focus on advanced diagnostics and strategic partnerships underscores a commitment to innovation and market leadership. While facing regulatory challenges and market uncertainties, Quest Diagnostics remains poised to leverage opportunities in consumer testing and data monetization. By navigating challenges and capitalizing on opportunities, Quest Diagnostics aims to sustain growth and drive value for stakeholders.

Quest Diagnostics reports robust Q1 growth and raises full-year guidance

Quest Diagnostics demonstrated strong financial performance and growth in Q1 2026, driven by revenue expansion and profitability improvements. The company's strategic focus on innovation, new clinical areas, and productivity enhancements positions it well for future success and market expansion. While facing challenges related to operational dynamics and potential expenses, Quest Diagnostics remains optimistic about its growth trajectory and opportunities ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to physicians, hospitals, patients, and consumers. The All Other segment consists of risk assessment services and healthcare information technology. The company was founded in 1967 and is headquartered in Secaucus, NJ.